[go: up one dir, main page]

WO1999053953A3 - Methodes et produits concernant les interactions metaboliques dans les maladies - Google Patents

Methodes et produits concernant les interactions metaboliques dans les maladies Download PDF

Info

Publication number
WO1999053953A3
WO1999053953A3 PCT/US1999/006874 US9906874W WO9953953A3 WO 1999053953 A3 WO1999053953 A3 WO 1999053953A3 US 9906874 W US9906874 W US 9906874W WO 9953953 A3 WO9953953 A3 WO 9953953A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
disease
products related
metabolic interactions
metabolic
Prior art date
Application number
PCT/US1999/006874
Other languages
English (en)
Other versions
WO1999053953A2 (fr
Inventor
Martha K Newell
Original Assignee
Univ Vermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vermont filed Critical Univ Vermont
Priority to EP99915109A priority Critical patent/EP1077724A2/fr
Priority to AU33705/99A priority patent/AU768656B2/en
Priority to CA002324995A priority patent/CA2324995A1/fr
Priority to JP2000544356A priority patent/JP2002512203A/ja
Publication of WO1999053953A2 publication Critical patent/WO1999053953A2/fr
Publication of WO1999053953A3 publication Critical patent/WO1999053953A3/fr
Priority to AU2004201144A priority patent/AU2004201144B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)

Abstract

La présente invention concerne des méthodes de régulation de la croissance et de la division cellulaires qui permettent de maîtriser des processus morbides par manipulation du métabolisme mitochondrial et par expression des protéines immunitaires de la surface cellulaire. L'invention concerne également des compositions et des essais de criblage connexes.
PCT/US1999/006874 1998-04-17 1999-03-30 Methodes et produits concernant les interactions metaboliques dans les maladies WO1999053953A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP99915109A EP1077724A2 (fr) 1998-04-17 1999-03-30 Methodes et produits concernant les interactions metaboliques dans les maladies
AU33705/99A AU768656B2 (en) 1998-04-17 1999-03-30 Methods and products related to metabolic interactions in disease
CA002324995A CA2324995A1 (fr) 1998-04-17 1999-03-30 Methodes et produits concernant les interactions metaboliques dans les maladies
JP2000544356A JP2002512203A (ja) 1998-04-17 1999-03-30 疾患における代謝的相互作用に関連する方法および製品
AU2004201144A AU2004201144B2 (en) 1998-04-17 2004-03-18 Methods and products related to metabolic interactions in disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8225098P 1998-04-17 1998-04-17
US60/082,250 1998-04-17
US9451998P 1998-07-29 1998-07-29
US60/094,519 1998-07-29
US10158098P 1998-09-24 1998-09-24
US60/101,580 1998-09-24

Publications (2)

Publication Number Publication Date
WO1999053953A2 WO1999053953A2 (fr) 1999-10-28
WO1999053953A3 true WO1999053953A3 (fr) 2000-01-13

Family

ID=27374244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006874 WO1999053953A2 (fr) 1998-04-17 1999-03-30 Methodes et produits concernant les interactions metaboliques dans les maladies

Country Status (5)

Country Link
EP (1) EP1077724A2 (fr)
JP (1) JP2002512203A (fr)
AU (1) AU768656B2 (fr)
CA (1) CA2324995A1 (fr)
WO (1) WO1999053953A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
US6599710B1 (en) * 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
DE60044087D1 (de) 1999-06-23 2010-05-12 Univ Vermont Verfahren und mittels zur manipulierung der expression des uncoupling proteins
US6365796B1 (en) 2000-02-16 2002-04-02 Beth Israel Deaconess Medical Center Transgenic UCP2 knockout mouse and use thereof
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
US6670138B2 (en) 2000-11-01 2003-12-30 Agy Therapeutics, Inc. Method of diagnosing ischemic stroke via UCP-2 detection
ATE530635T1 (de) 2001-08-21 2011-11-15 Ventana Med Syst Inc Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status
WO2005077065A2 (fr) * 2004-02-09 2005-08-25 The Regents Of The University Of California Ligands polyvalents selectifs a haute affinite et methodes de fabrication
RU2450273C2 (ru) * 2006-06-20 2012-05-10 Дженентек, Инк. Способы и материалы для обнаружения апоптоза
ES2554168T3 (es) * 2008-04-18 2015-12-16 Baxter International Inc. Composición basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nueva aparición
CN102083850B (zh) 2008-04-21 2015-08-12 加利福尼亚大学董事会 选择性高亲和力多齿配体及其制备方法
EA201391245A1 (ru) * 2011-03-02 2014-05-30 Берг Ллк Интеррогативные клеточные анализы и их применение
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
WO2015057968A2 (fr) 2013-10-17 2015-04-23 The General Hospital Corporation Méthodes pour identifier des sujets répondant au traitement d'une maladie auto-immune et compositions pour traiter ces sujets
JP6213939B2 (ja) * 2014-06-27 2017-10-18 国立大学法人名古屋大学 標本作製用包埋剤、硬化性基材非浸透標本の作製方法、硬化性基材浸透標本の作製方法、硬化性基材非浸透標本、凍結包埋剤の薄切性改善剤、及び凍結包埋剤
ES2962885T3 (es) 2015-05-15 2024-03-21 Massachusetts Gen Hospital Anticuerpos antagonistas de la superfamilia del receptor del factor de necrosis tumoral
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
CN116715767A (zh) 2016-05-13 2023-09-08 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002579A1 (fr) * 1996-07-12 1998-01-22 Emory University Regulation de l'apoptose et modele in vitro destine a des recherches en la matiere

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002579A1 (fr) * 1996-07-12 1998-01-22 Emory University Regulation de l'apoptose et modele in vitro destine a des recherches en la matiere

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; STREET D ET AL: "Interferon-gamma enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells.", XP002122832, retrieved from STN Database accession no. 97302905 *
GENESTIER L ET AL: "Caspase-dependent ceramide production in Fas - and HLA class I-mediated peripheral T cell apoptosis.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1998 FEB 27) 273 (9) 5060-6., XP002122830 *
GYNECOLOGIC ONCOLOGY, (1997 MAY) 65 (2) 265-72. *
HERMESH O ET AL: "Mitochondria uncoupling by a long chain fatty acyl analogue.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1998 FEB 13) 273 (7) 3937-42., XP002122831 *
LEE J W ET AL: "HLA-DR-mediated signals for hematopoiesis and induction of apoptosis involve but are not limited to a nitric oxide pathway.", BLOOD, (1997 JUL 1) 90 (1) 217-25., XP002122829 *
SATOH T ET AL: "CHANGES IN MITOCHONDRIAL MEMBRANE POTENTIAL DURING OXIDATIVE STRESS-INDUCED APOPTOSIS IN PC12 CELLS", JOURNAL OF NEUROSCIENCE RESEARCH,US,WILEY-LISS, vol. 50, no. 3, pages 413-420, XP002058714, ISSN: 0360-4012 *
SCAFFIDI C ET AL: "Two CD95 ( APO - 1 / Fas ) signaling pathways.", EMBO JOURNAL, (1998 MAR 16) 17 (6) 1675-87., XP002122827 *
SUMMERFIELD A ET AL: "Lymphocyte apoptosis during classical swine fever: implication of activation-induced cell death.", JOURNAL OF VIROLOGY, (1998 MAR) 72 (3) 1853-61., XP002122828 *

Also Published As

Publication number Publication date
AU768656B2 (en) 2003-12-18
JP2002512203A (ja) 2002-04-23
WO1999053953A2 (fr) 1999-10-28
CA2324995A1 (fr) 1999-10-28
EP1077724A2 (fr) 2001-02-28
AU3370599A (en) 1999-11-08

Similar Documents

Publication Publication Date Title
WO1999053953A3 (fr) Methodes et produits concernant les interactions metaboliques dans les maladies
NO975674L (no) Fremgangsmåte for å regulere sialyleringen av proteiner fremstilt av pattedyrceller i kultur
WO1999042077A3 (fr) Compositions et procedes de regulation de l'activation des lymphocytes
MX9605450A (es) Tratamiento para ateroesclerosis y otras enfermedades cardiovasculares e inflamatorias.
WO1999061619A8 (fr) Genes et proteines de cycle cellulaire et leurs utilisations
IL117425A0 (en) Receptor activation by gas6
WO2003045427A3 (fr) Composition pharmaceutique servant a induire une reponse immune chez l'homme ou chez l'animal
HUP9801370A3 (en) Stable protein:phospholipid compositions and methods for production thereof
CA2413156A1 (fr) Vecteurs d'expression
GB9518323D0 (en) Materials and methods relating to the attachment and display of substances on cell surfaces
EP0754229A1 (fr) L'alfamine, une proteine albuminoide serique humaine
IE830945L (en) Process for obtaining permanently culturable animal and¹human cell lines
WO2001004282A3 (fr) Vecteurs anti-cancereux de replication
ZA991707B (en) Methods and compositions for regulating cell death and enhancing disease resistance to plant pathogen.
HK1044956A1 (zh) 重組細胞聚變份子
FR2757505B1 (fr) Procede de production d'isobutene de haute purete combinant une distillation reactive d'hydroisomerisation, une distillation et une isomerisation squelettale
AU4350796A (en) Improvements in or relating to the control of production processes
AU2003204353A1 (en) Methods and compositions for enhancing immune response and for the production of in vitro mabs
AU7423391A (en) Dna constructs for the expression of proteins in the mammary gland of transgenetic mammals
FR2757506B1 (fr) Procede de production d'isobutene de haute purete combinant une distillation reactive d'hydroisomerisation et une isomerisation squelettale
HK1040420A1 (zh) 新陳代謝的選擇方法
AU4859599A (en) Method for producing a peptide with a pi above 8 or below 5
WO2002090510A3 (fr) Regulation de reponses immunes a l'aide de cellules dendritiques
WO2000037645A3 (fr) Acides nucleiques intervenant dans le cycle cellulaire, polypeptides et leurs utilisations
EP0754757A3 (fr) Promoteur végétal et son utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 33705/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2324995

Country of ref document: CA

Ref country code: CA

Ref document number: 2324995

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 544356

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999915109

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999915109

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 33705/99

Country of ref document: AU